Piribo: The search for blockbusters has never been greater and what's in the pipelines has never generated more interest.

Too few novel products and an aggressive generic sector are taking their toll … There are many prophets of doom all too ready to write off the research based pharma industry in the future.

And there is plenty on which to base such anxiety. The research-based industry must achieve a fair price in the face of greater cost control, while the burden of red tape and regulation is setting the bar high for successful product introduction. All the time the generics sector eats away at ageing and established portfolios.

It is a fair assessment to say that the industry, in the 1990s, rested too much on its laurels and successful product portfolios. For many years, too few truly novel medicines were brought to market, laying the foundations for the industry's current ills.
This 400-page report evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond:
Unique sales forecasts by major product to 2010 and beyond
100 key products assessed
Eight key therapy areas covered
Likelihood to launch assessment
Unique competitor evaluation scores
Critical and detailed appraisal of the research and development background
Detailed background and market context

“New Drug Futures” is available in hard copy and PDF format from Piribo. For more information go to: http://www.piribo.com/search/results.html?k=ESP892&x=3&y=10

Piribo Product ID: ESP892

About Piribo.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,500 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.